Experience in the use of collagenase clostridium histolyticum in the management of Peyronie's disease: Current data and future prospects - Abstract

INTRODUCTION: Peyronie's disease (PD) is a chronic wound-healing disorder characterized by formation of fibrous inelastic scarring of the tunica albuginea resulting in a variety of penile deformities. In most cases, PD is accompanied by a physical and psychological impact. Xiaflex® is an injectable collagenase clostridium histolyticum (CCh) preparation consisting of a predetermined mixture of two distinct collagenases. Recently the US Food and Drug Administration (FDA) approved Xiaflex® for the nonsurgical treatment of men with PD with curvature of 30° or more and tangible scar tissue plaque in their penis.

METHOD: This article presents a comprehensive review of the updated information on the use of Xiaflex® for the nonsurgical treatment of PD.

RESULTS: Mean improvements in penile curvature ranging from 29% to 34% and in bother domain scores have been reported. The majority of the reported adverse effects are mild or moderate and 79% resolve without intervention.

CONCLUSION: The combined results of these trials have led to the FDA approval of CCh for the treatment of PD. However, the long-term effects and results need further investigation, with large follow-up series. Considering these results, future perspectives will probably result in the use of a combined or sequential therapy including CCh.

Written by:
Egui Rojo MA, Moncada Iribarren I, Carballido Rodriguez J, Martinez-Salamanca JI.   Are you the author?
Urology Department, Hospital Universitario de Fuenlabrada, Madrid, Spain; Department of Urology, Hospital de la Zarzuela, Madrid, Spain; Department of Urology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain; Department of Urology, Hospital Puerta de Hierro-Majadahonda, Universidad Autónoma de Madrid, C/ Manuel de Falla no. 1, Majadahonda 28222, Madrid, Spain.

Reference: Ther Adv Urol. 2014 Oct;6(5):192-7.
doi: 10.1177/1756287214537331

PubMed Abstract
PMID: 25276229

Go "Beyond the Abstract" - Read an article written by the authors for UroToday.com

UroToday.com Peyronie's Section


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.